Fibromyalgia & musculoskeletal pain
Long versus short-term opioid therapy for fibromyalgia syndrome and risk of depression, sleep disorders and suicidal ideation: a population-based, propensity-weighted cohort study
Authors' conclusion
These findings suggest that continued opioid use for 90 days or more may aggravate depression and sleep problems in patients with FMS when compared with patterns of short-term treatment.
Study context
- Population
- Adults who received an initial opioid prescription specifically for FM, 2014 to 2018, population-wide databases covering five million inhabitants
- Participants
- 10,334 adults
- Exposure
- Long-term vs short-term initial opioid prescription for FM
- Long-termn = 2,025
- Short-termn = 8,309reference
- Outcome
- Depression, sleep disorders or suicidal ideation
Methodological detailspopulation-based, propensity-weighted (inverse probability of treatment weighting), multivariable Cox regression
- Population-based
- Propensity-weighted (inverse probability of treatment weighting)
- Multivariable Cox regression
Main finding
As reported in the abstract
Depression, sleep disorder and suicidal ideation (main adjusted analyses)
Long-term vs Short-termHazard ratio (95% CI)
Depression
1.58(1.29–1.95)
Sleep disorder
1.30(1.09–1.55)
Suicidal ideation
1.59(0.96–2.62)
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Long versus short-term opioid therapy for fibromyalgia syndrome and risk of depression, sleep disorders and suicidal ideation: a population-based, propensity-weighted cohort study. RMD Open. Published 23 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →